The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells
South San Francisco, CA, June 25, 2026 – The California Institute for Regenerative Medicine (CIRM) governing board today approved funding...
SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease
In a clinical first, Tr1X Bio showed immune reconstitution and
South San Francisco, CA, June 25, 2026 – The California